{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:10:42Z","timestamp":1789085442548,"version":"build-2803163510"},"reference-count":247,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272769"],"award-info":[{"award-number":["82272769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473891"],"award-info":[{"award-number":["82473891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972392"],"award-info":[{"award-number":["81972392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jare.2025.11.049","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:09:52Z","timestamp":1764029392000},"page":"995-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The landscape of genitourinary cancer vaccines: clinical advances and future opportunities"],"prefix":"10.1016","volume":"86","author":[{"given":"Ruoxuan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-5413","authenticated-orcid":false,"given":"Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-0411","authenticated-orcid":false,"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2025.11.049_b0005","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2023","key":"10.1016\/j.jare.2025.11.049_b0010","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jare.2025.11.049_b0015","unstructured":"National Cancer Institute (NIH). Cancer Treatment Vaccines. NIH; 2019."},{"key":"10.1016\/j.jare.2025.11.049_b0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox","volume":"367","author":"Moore","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2025.11.049_b0025","first-page":"8","article-title":"Strategies for developing and optimizing cancer vaccines","author":"Maeng","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.jare.2025.11.049_b0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0035","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.2003.06.041","article-title":"Current developments in cancer vaccines and cellular immunotherapy","volume":"21","author":"Ribas","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0040","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/hv.19795","article-title":"Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer","volume":"8","author":"Gardner","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.11.049_b0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0055","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s43018-025-00944-z","article-title":"Personalized neoantigen vaccines in urologic malignancies","volume":"6","author":"Jazayeri","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0060","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.scib.2025.01.016","article-title":"Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers","volume":"70","author":"Hu","year":"2025","journal-title":"Sci Bull"},{"key":"10.1016\/j.jare.2025.11.049_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B cells as antigen presenting cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b1230","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","article-title":"Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0085","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12\u20132021","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0090","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.11.049_b0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0100","article-title":"Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2025.11.049_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jare.2025.11.049_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0120","article-title":"From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor","volume":"101322","author":"You","year":"2025","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.jare.2025.11.049_b0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jare.2025.11.049_b0130","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers\u2014current landscape and future directions","volume":"15","author":"Shanshal","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jare.2025.11.049_b0135","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0140","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/2326-6066.CIR-15-0134","article-title":"Neoepitopes of cancers: looking back, looking ahead","volume":"3","author":"Srivastava","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2025.11.049_b0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08830185.2017.1298749","article-title":"Cytosolic nucleic acid sensors and innate immune regulation","volume":"36","author":"Ori","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0150","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1586\/erv.09.79","article-title":"Intracellular detection and immune signaling pathways of DNA vaccines","volume":"8","author":"Tang","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jare.2025.11.049_b0155","article-title":"Oral S2-Ag85 DNA vaccine activated intestinal cell dsDNA and RNA sensors to promote the presentation of intestinal antigen","author":"Dang","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jare.2025.11.049_b0160","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","article-title":"Vaccines as treatments for prostate cancer","volume":"20","author":"Rastogi","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0165","article-title":"Mechanism of LncRNA Gm2044 in germ cell development","volume":"12","author":"Zhu","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jare.2025.11.049_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn9961","article-title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","volume":"10","author":"Fan","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jare.2025.11.049_b0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0180","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jare.2025.11.049_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0190","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","article-title":"Several common HLA-DR types share largely overlapping peptide binding repertoires","volume":"160","author":"Southwood","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0195","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0200","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.7150\/thno.38742","article-title":"Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jare.2025.11.049_b0205","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/08830180600992498","article-title":"GM-CSF gene-modifed cancer cell immunotherapies: of mice and men","volume":"25","author":"Hege","year":"2006","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0215","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-5347(17)35032-2","article-title":"Demonstration of a rational strategy for human prostate cancer gene therapy","volume":"151","author":"Sanda","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0220","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4049\/jimmunol.1400004","article-title":"Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response","volume":"193","author":"Zhao","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0225","doi-asserted-by":"crossref","first-page":"32351","DOI":"10.1038\/srep32351","article-title":"Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2025.11.049_b0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000282","article-title":"Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma","volume":"8","author":"Wang-Bishop","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0240","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1172\/JCI65698","article-title":"Peptidases released by necrotic cells control CD8+ T cell cross-priming","volume":"123","author":"Gamrekelashvili","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2025.11.049_b0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001369","article-title":"Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity","volume":"8","author":"Efimova","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0250","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201703969","article-title":"Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity","volume":"29","author":"Kroll","year":"2017","journal-title":"Adv Mater"},{"key":"10.1016\/j.jare.2025.11.049_b0255","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202001808","article-title":"Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity","volume":"32","author":"Jiang","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.jare.2025.11.049_b0260","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1021\/acsami.2c22363","article-title":"Surgically derived cancer cell membrane-coated R837-loaded poly(2-oxazoline) nanoparticles for prostate cancer immunotherapy","volume":"15","author":"Li","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.jare.2025.11.049_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114107","article-title":"Nanovaccines with cell-derived components for cancer immunotherapy","volume":"182","author":"Meng","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jare.2025.11.049_b0270","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1021\/acsnano.6b03148","article-title":"Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer","volume":"10","author":"Cao","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jare.2025.11.049_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112803","article-title":"Biomimetic fabrication of nanotherapeutics by leukocyte membrane cloaking for targeted therapy","volume":"219","author":"Mohale","year":"2022","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.jare.2025.11.049_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2020.05.028","article-title":"Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy","volume":"112","author":"Chen","year":"2020","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jare.2025.11.049_b0285","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell-based cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.iy.09.040191.001415","article-title":"The dendritic cell system and its role in immunogenicity","volume":"9","author":"Steinman","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0295","article-title":"Programmable macrophage vesicle based bionic self-adjuvanting vaccine for immunization against monkeypox virus","volume":"12","author":"Lin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jare.2025.11.049_b0300","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0305","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.11.049_b0310","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3390\/ijms26052056","article-title":"Living bacteria: a new vehicle for vaccine delivery in cancer immunotherapy","volume":"26","author":"Yang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2025.11.049_b0315","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0320","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/cr.2016.153","article-title":"Immunotherapy against cancer-related viruses","volume":"27","author":"Tashiro","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.jare.2025.11.049_b0325","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An overview of novel adjuvants designed for improving vaccine efficacy","volume":"38","author":"Bonam","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jare.2025.11.049_b0330","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41590-022-01168-4","article-title":"Making innate sense of mRNA vaccine adjuvanticity","volume":"23","author":"Kobiyama","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0335","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0340","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","article-title":"Recent progress in targeted delivery vectors based on biomimetic nanoparticles","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0345","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010045","article-title":"Nanoparticles as adjuvants and nanodelivery systems for mRNA-based vaccines","volume":"13","author":"Alfagih","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jare.2025.11.049_b0350","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0355","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jare.2025.11.049_b0360","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2015.986104","article-title":"Lipid-based mRNA vaccine delivery systems","volume":"14","author":"Midoux","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jare.2025.11.049_b0365","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery","volume":"10","author":"Ho","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.jare.2025.11.049_b0370","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1039\/C8BM00908B","article-title":"Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine","volume":"6","author":"Fan","year":"2018","journal-title":"Biomater Sci"},{"key":"10.1016\/j.jare.2025.11.049_b0375","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/acs.jmedchem.6b01556","article-title":"Enhanced spacer length between mannose mimicking shikimoyl and quinoyl headgroups and hydrophobic region of cationic amphiphile increases efficiency of dendritic cell based DNA vaccination: a structure-activity investigation","volume":"60","author":"Voshavar","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2025.11.049_b0380","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition","volume":"11","author":"Kong","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jare.2025.11.049_b0385","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jare.2025.11.049_b0390","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","article-title":"Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges","volume":"45","author":"Gomes-da-Silva","year":"2012","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.jare.2025.11.049_b0395","article-title":"Tissue-specific mRNA delivery and prime editing with peptide\u2013ionizable lipid nanoparticles","author":"Lin","year":"2025","journal-title":"Nat Mater"},{"key":"10.1016\/j.jare.2025.11.049_b0400","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1039\/D4CC06510G","article-title":"Immunoadjuvant-functionalized metal-organic frameworks: synthesis and applications in tumor immune modulation","volume":"61","author":"Zhao","year":"2025","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.jare.2025.11.049_b0405","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.actbio.2019.07.003","article-title":"DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen","volume":"96","author":"Cole","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jare.2025.11.049_b0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01333","article-title":"Development of spherical nucleic acids for prostate cancer immunotherapy","volume":"11","author":"Qin","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_bib1231","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.vaccine.2008.03.095","article-title":"Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?","volume":"26","author":"Lambert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jare.2025.11.049_b0415","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2025.11.049_b0420","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1464-410X.2009.08745.x","article-title":"A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma","volume":"105","author":"Baillargeon-Gagne","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.jare.2025.11.049_b0425","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.09.027","article-title":"Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function","volume":"67","author":"Capitanio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0430","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1245\/s10434-012-2247-0","article-title":"Treatment management of small renal masses in the 21st century: a paradigm shift","volume":"19","author":"Sun","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0435","first-page":"5818","article-title":"Integrated functional genomics approach for the design of patient-individual antitumor vaccines","volume":"62","author":"Weinschenk","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b0440","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/13543784.2013.822066","article-title":"IMA901: a peptide vaccine in renal cell carcinoma","volume":"22","author":"Jens","year":"2013","journal-title":"Expert Opin Investig Drug"},{"key":"10.1016\/j.jare.2025.11.049_b0445","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0450","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(98)00013-8","article-title":"The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review","volume":"79","author":"Csermely","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0455","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/neuonc\/nou054","article-title":"Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial","volume":"16","author":"Bloch","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0460","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-5876-8-9","article-title":"Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma","volume":"8","author":"Eton","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2025.11.049_b0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.20.100301.064801","article-title":"Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses","volume":"20","author":"Srivastava","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0470","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/14712598.1.3.539","article-title":"HSPPC-96: a personalised cancer vaccine","volume":"1","author":"Caudill","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0475","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2025.11.049_b0480","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","article-title":"Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results","volume":"3","author":"Amin","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0485","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2220629","article-title":"A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma","volume":"19","author":"DeBenedette","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0490","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt.11.160","article-title":"TroVax(\u00ae) vaccine therapy for renal cell carcinoma","volume":"4","author":"Zhang","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jare.2025.11.049_b0495","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00262-012-1302-9","article-title":"Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4","volume":"61","author":"Harrop","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0500","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b0505","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.4049\/jimmunol.1101644","article-title":"Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice","volume":"188","author":"Zhao","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0510","unstructured":"US National Library of Medicine, ClinicalTrials.gov, 2023."},{"key":"10.1016\/j.jare.2025.11.049_b0515","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2015.04.015","article-title":"AIM2 co-immunization favors specific multifunctional CD8(+) T cell induction and ameliorates coxsackievirus B3-induced chronic myocarditis","volume":"119","author":"Chai","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jare.2025.11.049_b0520","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature07725","article-title":"AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC","volume":"458","author":"Hornung","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jare.2025.11.049_b0525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/imr.12618","article-title":"The AIM2 inflammasome: Sensor of pathogens and cellular perturbations","volume":"281","author":"Lugrin","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jare.2025.11.049_b0530","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/1535-7163.MCT-18-0832","article-title":"Combining DNA vaccine and AIM2 in H1 nanoparticles exert anti-renal carcinoma effects via enhancing tumor-specific multi-functional CD8(+) T-cell responses","volume":"18","author":"Chai","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2021.11.017","article-title":"Dual-targeting vaccine of FGL1\/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity","volume":"24","author":"Chai","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jare.2025.11.049_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110722","article-title":"Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors","volume":"123","author":"Ding","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jare.2025.11.049_b0545","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13073-020-00731-8","article-title":"Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy","volume":"12","author":"Reustle","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.jare.2025.11.049_b0550","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-021-01465-w","article-title":"Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1038807","article-title":"Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma","volume":"13","author":"Oladejo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0560","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jare.2025.11.049_b0565","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1643533","article-title":"Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0570","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.11.049_b0575","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41391-022-00618-2","article-title":"Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer","volume":"26","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jare.2025.11.049_b0580","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12951-024-02438-z","article-title":"MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC","volume":"22","author":"Wang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.jare.2025.11.049_b0585","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.40489","article-title":"SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jare.2025.11.049_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2019.03.002","article-title":"Emerging therapeutic targets for patients with advanced prostate cancer","volume":"76","author":"Saad","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jare.2025.11.049_b0595","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0600","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004198","article-title":"Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)","volume":"10","author":"McNeel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0605","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.4161\/hv.29553","article-title":"mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer","volume":"10","author":"Rausch","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0610","doi-asserted-by":"crossref","unstructured":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study, Journal for ImmunoTherapy of Cancer, 3 (2015) 26.","DOI":"10.1186\/s40425-015-0068-y"},{"key":"10.1016\/j.jare.2025.11.049_b0615","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx376.014","article-title":"1149PResults of the randomized, placebo-controlled phase I\/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"28","author":"Stenzl","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0620","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b0625","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.19.03141","article-title":"Clinical cancer advances 2020: annual report on progress against cancer from the american society of clinical oncology","volume":"38","author":"Markham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0630","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0635","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4543861","article-title":"Sipuleucel-T and androgen receptor-directed therapy for castration-resistant prostate cancer: a meta-analysis","volume":"2016","author":"Yi","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jare.2025.11.049_b0640","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/14737140.2014.856270","article-title":"Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer","volume":"14","author":"Holko","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0645","doi-asserted-by":"crossref","first-page":"18192","DOI":"10.18632\/oncotarget.4145","article-title":"Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer","volume":"6","author":"Podrazil","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jare.2025.11.049_b0650","article-title":"Autologous dendritic cell vaccination (DCVAC\/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer","volume":"33","author":"Nicholas","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0655","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0660","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0665","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0670","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eururo.2014.12.010","article-title":"A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802","volume":"68","author":"DiPaola","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0675","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010851","article-title":"Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer","volume":"13","author":"Lassoued","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0680","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1490856","article-title":"CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy","volume":"7","author":"Zafar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jare.2025.11.049_b0685","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265717","article-title":"Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy","volume":"6","author":"Zafar","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jare.2025.11.049_b0690","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2020.222","article-title":"Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples","volume":"32","author":"Zafar","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0695","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jare.2025.11.049_b0700","unstructured":"Japan Registry of Clinical Trials, Oncolytic herpes simplex virus type I (HSV-1) virus therapy using G47delta for patients with prostate cancer, JRCT, 2022."},{"key":"10.1016\/j.jare.2025.11.049_b0705","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1634\/theoncologist.2019-0932","article-title":"Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors","volume":"25","author":"Collins","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2025.11.049_b0710","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005702","article-title":"First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)","volume":"11","author":"Autio","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0715","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00262-008-0463-z","article-title":"Development of a listeria monocytogenes based vaccine against prostate cancer","volume":"57","author":"Shahabi","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0720","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/CVI.00274-08","article-title":"Construction and characterization of an attenuated listeria monocytogenes strain for clinical use in cancer immunotherapy","volume":"16","author":"Wallecha","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0725","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00262-012-1257-x","article-title":"Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer","volume":"61","author":"Hannan","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0730","article-title":"Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress","volume":"6","author":"Flickinger","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jare.2025.11.049_b0735","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fcimb.2014.00051","article-title":"Attenuated listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy","volume":"4","author":"Wood","year":"2014","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jare.2025.11.049_b0740","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41391-021-00402-8","article-title":"Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer","volume":"25","author":"Drake","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jare.2025.11.049_b0745","unstructured":"US National Library of Medicine, ClinicalTrials.gov, 2016."},{"key":"10.1016\/j.jare.2025.11.049_b0750","first-page":"17","article-title":"Control of prostate growth","volume":"17","author":"Coffey","year":"1981","journal-title":"Urology"},{"key":"10.1016\/j.jare.2025.11.049_b0755","article-title":"Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy","volume":"7","author":"Coventry","year":"2019","journal-title":"Ther Adv Vaccines Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0760","first-page":"210","article-title":"Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0765","article-title":"What do we have to know about PD-L1 expression in prostate cancer? a systematic literature review. Part 1: focus on immunohistochemical results with discussion of pre-analytical and interpretation variables","volume":"10","author":"Palicelli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jare.2025.11.049_b0770","first-page":"1181","article-title":"The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma","volume":"7","author":"von Mehren","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b0775","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1634\/theoncologist.2010-0129","article-title":"Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","volume":"15","author":"Madan","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2025.11.049_b0780","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1186\/s12967-025-06867-8","article-title":"Reversing the \u201ccold\u201d tumor microenvironment: the role of neoantigen vaccines in prostate cancer","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2025.11.049_b0785","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0790","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0795","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0800","first-page":"10","article-title":"Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer","volume":"7","author":"Liakou","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jare.2025.11.049_b0805","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0810","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2019.02.005","article-title":"BCG-induced formation of neutrophil extracellular traps play an important role in bladder cancer treatment","volume":"201","author":"Liu","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0815","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3389\/fimmu.2020.01202","article-title":"Characterizing the BCG induced macrophage and neutrophil mechanisms for defense against mycobacterium tuberculosis","volume":"11","author":"Bickett","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0820","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.5306","article-title":"Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches","volume":"249","author":"Song","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.jare.2025.11.049_b0825","doi-asserted-by":"crossref","unstructured":"Pettenati, Caroline, Ingersoll, Molly, A., Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urology, (2018).","DOI":"10.1038\/s41585-018-0055-4"},{"key":"10.1016\/j.jare.2025.11.049_b0830","article-title":"Systemic immune response after intravesical instillation of bacille Calmette\u2013Gu\u00e9rin (BCG) for superficial bladder cancer","volume":"115","author":"Taniguchi","year":"2010","journal-title":"Clin & Exp Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0835","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.jare.2025.11.049_b0840","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0845","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2007.08.015","article-title":"Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results","volume":"53","author":"Witjes","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0850","first-page":"1790","article-title":"Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy","volume":"10","author":"Punnen","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0855","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1128\/JB.00336-06","article-title":"A functional dlt operon, encoding proteins required for incorporation of d-alanine in teichoic acids in gram-positive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae","volume":"188","author":"Kovacs","year":"2006","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jare.2025.11.049_b0860","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1099\/mic.0.045997-0","article-title":"The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile","volume":"157","author":"McBride","year":"2011","journal-title":"Microbiology (Reading)"},{"key":"10.1016\/j.jare.2025.11.049_b0865","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/antibiotics3040461","article-title":"Antimicrobial peptide resistance mechanisms of gram-positive bacteria","volume":"3","author":"Nawrocki","year":"2014","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jare.2025.11.049_b0870","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1128\/MMBR.67.4.686-723.2003","article-title":"A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria","volume":"67","author":"Neuhaus","year":"2003","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.jare.2025.11.049_b0875","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbrc.2018.12.097","article-title":"The immunotherapeutic effects of recombinant bacillus Calmette-Guerin resistant to antimicrobial peptides on bladder cancer cells","volume":"509","author":"Cho","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jare.2025.11.049_b0880","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fimmu.2019.01460","article-title":"In vitro evidence of human immune responsiveness shows the improved potential of a recombinant BCG strain for bladder cancer treatment","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b0885","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030694","article-title":"From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in bacillus calmette-guerin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC)","volume":"14","author":"Deininger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2025.11.049_b0890","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1748981","volume":"9","author":"Rentsch","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jare.2025.11.049_b0895","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002371-200403000-00005","article-title":"Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma","volume":"27","author":"Arnold","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0900","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-009-0673-z","article-title":"Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0905","doi-asserted-by":"crossref","unstructured":"Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol, Chapter 14 (2013) Unit 14 25.","DOI":"10.1002\/0471141755.ph1425s61"},{"key":"10.1016\/j.jare.2025.11.049_b0910","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MD.0000000000004764","article-title":"Cancer stem cells: understanding tumor hierarchy and heterogeneity","volume":"95","author":"Rich","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jare.2025.11.049_b0915","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00018-016-2210-5","article-title":"Effects of radiation on metastasis and tumor cell migration","volume":"73","author":"Vilalta","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jare.2025.11.049_b0920","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13287-015-0211-1","article-title":"Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine","volume":"6","author":"Zhu","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jare.2025.11.049_b0925","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2490-13-57","article-title":"A modified method for isolation of bladder cancer stem cells from a MB49 murine cell line","volume":"13","author":"Zhu","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.jare.2025.11.049_b0930","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.scr.2014.04.006","article-title":"The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer","volume":"13","author":"Zhu","year":"2014","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.jare.2025.11.049_b0935","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/ijc.31219","article-title":"PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine","volume":"142","author":"Shi","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b0940","doi-asserted-by":"crossref","first-page":"10151","DOI":"10.1016\/j.biomaterials.2013.09.041","article-title":"A cancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors","volume":"34","author":"Huang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jare.2025.11.049_b0945","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/138920306779025611","article-title":"Anticancer alpha-helical peptides and structure\/function relationships underpinning their interactions with tumour cell membranes","volume":"7","author":"Dennison","year":"2006","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.jare.2025.11.049_b0950","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3892\/ijo.2020.5099","article-title":"Anticancer peptide: physicochemical property, functional aspect and trend in clinical application","volume":"57","author":"Chiangjong","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0955","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.peptides.2011.04.024","article-title":"Pardaxin-induced apoptosis enhances antitumor activity in HeLa cells","volume":"32","author":"Hsu","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.jare.2025.11.049_b0960","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3390\/md9101995","article-title":"Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells","volume":"9","author":"Huang","year":"2011","journal-title":"Mar Drugs"},{"key":"10.1016\/j.jare.2025.11.049_b0965","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/jjco\/hys069","article-title":"Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer","volume":"42","author":"Obara","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0970","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/IR:36:1:197","article-title":"Complement-mediated activation of the adaptive immune responses - role of C3d in linking the innate and adaptive immunity","volume":"36","author":"Toapanta","year":"2006","journal-title":"Immunol Res"},{"key":"10.1016\/j.jare.2025.11.049_b0975","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00262-009-0727-2","article-title":"Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth","volume":"59","author":"Liang","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b0980","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2217\/fon-2016-0284","article-title":"Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer","volume":"12","author":"Keehn","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b0985","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1016\/j.vaccine.2021.06.049","article-title":"MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG","volume":"39","author":"Mart\u00edn","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jare.2025.11.049_b0990","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trsl.2018.03.004","article-title":"Therapeutic efficacy of the live-attenuated vaccine, MTBVAC, in a preclinical model of bladder cancer","volume":"197","author":"Alvarez-Arguedas","year":"2018","journal-title":"Transl Res"},{"key":"10.1016\/j.jare.2025.11.049_b0995","unstructured":"US National Library of Medicine, ClinicalTrials.gov, 2018."},{"key":"10.1016\/j.jare.2025.11.049_b1000","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/2326-6066.CIR-18-0671","article-title":"Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model","volume":"7","author":"Domingos-Pereira","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2025.11.049_b1005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/01.ju.0000103924.93206.93","article-title":"Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine","volume":"171","author":"Lee","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.jare.2025.11.049_b1010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00262-018-2197-x","article-title":"Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer","volume":"67","author":"Obara","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b1015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical bacillus calmette guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients","volume":"23","author":"Derr\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b1020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/1744-9987.12694","article-title":"Vaccination of urological cancer patients with WT1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses","volume":"22","author":"Ogasawara","year":"2018","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jare.2025.11.049_b1025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002459","article-title":"Systematic review of combinations of targeted or immunotherapy in advanced solid tumors","volume":"9","author":"Tan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b1030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102831","article-title":"Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"12","author":"Gamat-Huber","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2025.11.049_b1035","first-page":"2444","article-title":"Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade","volume":"60","author":"Hurwitz","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b1040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.2011-0234","article-title":"Phase II trial of neoadjuvant docetaxel and CG1940\/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer","volume":"18","author":"Vuky","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2025.11.049_b1045","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.11.049_b1050","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37234-6","article-title":"An oral cancer vaccine using vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model","volume":"13","author":"Ueki","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2025.11.049_b1055","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jare.2025.11.049_b1060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b1065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b1070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12967-016-0799-7","article-title":"Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions","volume":"14","author":"Wen","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2025.11.049_b1075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cyto.2016.01.009","article-title":"Effects of tumor vaccine expressing granulocyte-macrophage colony stimulating factor and interleukin-18 fusion on cancer cells and its possible application for cancer immunotherapy","volume":"89","author":"Lee","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jare.2025.11.049_b1080","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-16-3016","article-title":"Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma","volume":"23","author":"Butterfield","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.11.049_b1085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9020020","article-title":"Androgen receptor signaling in bladder cancer","volume":"9","author":"Li","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2025.11.049_b1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104120","article-title":"Roles for androgen receptor, ADAR2, and PD-L1 in primary urothelial carcinoma in situ of the bladder treated with bacillus calmette-gu\u00e9rin therapy","volume":"105","author":"Ricciardi","year":"2025","journal-title":"Lab Invest"},{"key":"10.1016\/j.jare.2025.11.049_b1095","doi-asserted-by":"crossref","first-page":"14153","DOI":"10.18632\/oncotarget.7358","article-title":"Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence","volume":"7","author":"Izumi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jare.2025.11.049_b1100","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-14-1055-T","article-title":"Antiandrogen therapy with hydroxyflutamide or androgen receptor degradation enhancer ASC-J9 enhances BCG efficacy to better suppress bladder cancer progression","volume":"14","author":"Shang","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2025.11.049_b1105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euros.2022.06.007","article-title":"Combining antiandrogens with immunotherapy for bladder cancer treatment","volume":"43","author":"Besan\u00e7on","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.jare.2025.11.049_b1110","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/s41598-017-03421-5","article-title":"Systematic review and cumulative analysis of the combination of mitomycin C plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer","volume":"7","author":"Deng","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2025.11.049_b1115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2025.11.049_b1120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40164-023-00457-4","article-title":"CRISPR\/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy","volume":"12","author":"Chen","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b1125","doi-asserted-by":"crossref","DOI":"10.1126\/science.ado9336","article-title":"Sequence modeling and design from molecular to genome scale with Evo","volume":"386","author":"Nguyen","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jare.2025.11.049_b1130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-023-01738-6","article-title":"Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b1135","article-title":"A clinical prognostic model related to T cells based on machine learning for predicting the prognosis and immune response of ovarian cancer","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jare.2025.11.049_b1140","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2025.11.049_b1145","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO precision medicine working group","volume":"31","author":"De Mattos-Arruda","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b1150","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2217\/fon-2022-0694","article-title":"KEYNOTE \u2013 D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma","volume":"18","author":"Long","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b1155","article-title":"allergen Der p 22: cloning, expression, IgE-binding in asthmatic children, and immunogenicity","volume":"33","author":"Zhou","year":"2022","journal-title":"Pediat Allerg Imm-Uk"},{"key":"10.1016\/j.jare.2025.11.049_b1160","article-title":"Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.jare.2025.11.049_b1165","article-title":"Computational cancer neoantigen prediction: current status and recent advances","volume":"12","author":"Fotakis","year":"2021","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.jare.2025.11.049_b1170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation","volume":"12","author":"Borden","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2025.11.049_b1175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1357217","article-title":"Personalized cancer vaccine design using AI-powered technologies","volume":"15","author":"Kumar","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.11.049_b1180","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41551-019-0351-1","article-title":"Exploration of the nanomedicine-design space with high-throughput screening and machine learning","volume":"3","author":"Yamankurt","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jare.2025.11.049_b1185","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41565-023-01323-4","article-title":"Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures","volume":"18","author":"Zhu","year":"2023","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jare.2025.11.049_b1190","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41578-021-00337-5","article-title":"Nanoparticle synthesis assisted by machine learning","volume":"6","author":"Tao","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.jare.2025.11.049_b1195","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwad214","article-title":"STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy","volume":"10","author":"Zhou","year":"2023","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.jare.2025.11.049_b1200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jare.2025.11.049_b1205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2025.11.049_b1210","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28836","article-title":"High sensitivity of cancer exome-based CD8 T cell neo-antigen identification","volume":"3","author":"Van Buuren","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jare.2025.11.049_b1215","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.174027","article-title":"CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy","volume":"8","author":"Huff","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jare.2025.11.049_b1220","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502904","article-title":"CD27 stimulation unveils the efficacy of linked class I\/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4\/CD8 T cell response","volume":"7","author":"Riccione","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jare.2025.11.049_b1225","doi-asserted-by":"crossref","DOI":"10.36922\/arnm.8350","article-title":"Current status and future potential of radiomics in the management of patients with gastric cancer","volume":"3","author":"Zheng","year":"2025","journal-title":"ARNM"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225009452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225009452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:45:05Z","timestamp":1789083905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225009452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":247,"alternative-id":["S2090123225009452"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.11.049","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The landscape of genitourinary cancer vaccines: clinical advances and future opportunities","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.11.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}